Eli Lilly & Co (LLY)

Common Stock
Sell: $1,035.91|Buy: $1,037.15|Change: 13.01 (1.27%)

Company profile

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltzand Olumiant for immunology.

Address

Lilly Corporate Center
Indianapolis
IN
USA
46285


Telephone

+1 317 2962884


Sector 

Healthcare


Previous key dates

NameKey Date
Eli Lilly and Co Annual Report for 20252026-02-19T00:00:00
Eli Lilly and Co Fourth Quarter Earnings Conference Call for 20252026-02-06T10:00:00
Eli Lilly and Co Fourth Quarter Earnings Result for 20252026-02-06T00:00:00
44th Annual J.P. Morgan Healthcare Conference2026-01-13T17:15:00
Citi's 2025 Global Healthcare Conference2025-12-02T10:30:00
Eli Lilly and Co Third Quarter Earnings Conference Call for 20252025-10-30T10:00:00
Eli Lilly and Co Third Quarter Earnings Result for 20252025-10-30T00:00:00
Bernstein's 2nd Annual Healthcare Forum2025-09-25T08:00:00
Morgan Stanley 23rd Annual Global Healthcare Conference2025-09-08T09:15:00
Wells Fargo 20th Annual Healthcare Conference2025-09-05T09:30:00
Eli Lilly and Co Second Quarter Earnings Conference Call for 20252025-08-07T08:30:00
Eli Lilly and Co Second Quarter Earnings Result for 20252025-08-07T00:00:00
Goldman Sachs 46th Annual Global Health Care Conference2025-06-10T08:00:00
Bank of America Securities 2025 Healthcare Conference2025-05-15T11:40:00
Eli Lilly and Co Annual General Meeting for 20252025-05-05T08:30:00
Eli Lilly and Co First Quarter Earnings Conference Call for 20252025-05-01T10:00:00
Eli Lilly and Co First Quarter Earnings Results for 20252025-05-01T00:00:00
TD Cowen 45th Annual Health Care Conference2025-03-10T09:20:00
TD Cowen's 45th Annual Health Care Conference2025-03-04T13:50:00
Eli Lilly and Co Annual Report for 20242025-02-19T00:00:00
Eli Lilly and Co Fourth Quarter Earnings Conference Call for 20242025-02-06T10:00:00
Eli Lilly and Co Fourth Quarter Earnings Result for 20242025-02-06T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.